Protein Concentration SOP: Bradford Assay

Shalaka Samant, PhD • January 21, 2020
Protein Concentration SOP: Bradford Assay

SOP: Protein Reagent Concentration

Determining Sample Consistency

Whether your lab already has an SOP in place for new protein analysis or would benefit from a revised procedure, we provide a simplified version of kbDNAs in-house Bradford Assay protocol for concentration testing commercial protein reagents.


Why concentration and why now?

> LAB REPLENISHING

Many researchers have begun ordering recombinant reagents as part of their material replenishing & it's important to revisit the role of concentration

> COVID IMPACT

Due to the unique disruption in the manufacturing sector, the likelihood of receiving proteins from the same batch (or lot) prior to COVID is low

> CONCENTRATION FACTOR

Measuring sample concentration and comparing it to the data on the certificate of analysis is the most direct way to determine whether any quality was impacted

> VERIFYING QUALITY

We suggest running Bradford assay tests on both same and different lot samples since the disruption could have occurred during the production or storage period

From Bottleneck to Benchmark: kbDNA’s Rituximab Biosimilar Purification Success Story

October 23, 2025
Discover kbDNA’s rapid workflow for repurifying rituximab biosimilars to high-purity standards—featuring SEC overlays, gel schematics, and SOPs.
Glowing blue and orange DNA strand against a dark background.

Current State of Discovery R&D | UnderReport kb

By Ed Hamdeh • October 13, 2025
Unfiltered truths, hidden risks, and real data behind life sciences R&D in North America. Discover the facts nobody else is sharing—read the full report now
A green and purple background with a pattern of flowers on it.

Biosimilars: Navigating the Landscape for Future Therapeutics

By Vaibhav Shah • May 17, 2025
This article explores the complexities of biosimilars, including their development process, regulatory challenges, economic impact, and future prospects. It highlights the potential of biosimilars to reduce healthcare costs and increase patient access to biologic therapies, providing valuable insights for biopharmaceutical and academic researchers.